ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint742,806 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryBaselGranite Bio AG
Granite Bio AG Logo
Verified· 3 sources

Granite Bio AG

Summary

About the company

Granite Bio AG is a biotechnology company developing first-in-class therapeutic antibodies for inflammatory, autoimmune and fibrotic diseases. Its pipeline includes GRT-001, an antibody that depletes pro-inflammatory monocytes and is in Phase 1b for inflammatory bowel disease, and GRT-002, an interleukin-3–blocking antibody in preclinical development expected to enter clinical trials in 2026.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
✓ Offered
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4
Development of therapeutic antibodies
Development of first-in-class antibodies against inflammation, autoimmunity and fibrosis; pipeline with GRT-001 and GRT-002 for selective immunomodulation and new therapeutic approaches.
Development of therapies for inflammation, autoimmunity and fibrosis
Development of agents against inflammatory, autoimmune and fibrotic diseases; focus on key disease mechanisms, immunomodulation and selective depletion of pathogenic cells.
GRT-001
Therapeutic antibody for the depletion of pro-inflammatory monocytes; Phase 1a completed, currently Phase 1b in inflammatory bowel disease.
GRT-002
Therapeutic antibody against interleukin-3; developed preclinically for autoimmune inflammation, type II inflammation, itch and allergy.
Press

Media

April 25, 2025Media
Granite Bio debuts with $100 million to tackle autoimmune diseases
startupticker.ch

Knowledge

No knowledge articles yet

Once Granite Bio AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Granite Bio AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Granite Bio AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Granite Bio AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Aeschenvorstadt 36
4051 Basel

At a glance

Legal form
Corporation
UID
CHE-465.152.120
Founded
2021 · 5 years
Last commercial register change
July 6, 2026
Employees
21 to 50

Similar companies

EP
Eumedica Pharmaceuticals AG
Basel
AP
Acadia Pharmaceuticals GmbH
Basel
BM
BeOne Medicines International GmbH
Basel
BM
BeOne Medicines I GmbH
Basel